3.
Molecular Signature Profiling, Identification of Molecules Carrying
Disease-Specific Spectral Properties
Based
on results of the Standard Spectral Survey and Advanced
Spectral Profile, the preparative and analytical conditions
are defined for molecular identification. Standard preparation
and spectral parameters will also be utilized to generate standardized
chromatographic patterns, and 'Molecular Signature Profiles'
for incorporation into the core SMI database for current and future
comparative analysis.
When
discriminatory molecular identification is initiated, the wavelength
providing the most significant discriminatory signal is selected
for molecular detection coupled to chromatographic methods. Discriminatory
signals established with HR-INFLIT technology provide the foundation
for utilization of the corresponding XL-INFLIT technology for
chromatographic analyses. SerOptix expects the spectral patterns
of the molecules eluted from molecular separation systems to reiterate
the discrimination of the aggregate preparations. The confirmation
of this effect by comparison of multiple diseased and control
samples provides significant scientific validation of the molecular
marker of the discriminatory signals.
Molecular Signature Profiling provides a standardized system
for identifying small molecular differences that may be undetectable
in the large background of the complex extracts, and also offers
a standardized comparator base for establishing disease-specific
patterns with future samples, and annotation with specific molecular
identifications. 
Figure 2. Identification
of disease-specific variations in fluorescent molecular profiles
between normal and HCV-infected plasma samples. Sample type, preparation
and analytical conditions were selected based on the results of
spectral profiling of samples extracted by multiple procedures.
Samples were analyzed by hydrophilic interaction high performance
liquid chromatography and solvent gradient elution.
The linkage of molecular indicators with diseases will dramatically
increase the value of the core Spectra-Molecular database and
significantly enhance its subscription value to diagnostic and
pharmaceutical companies.
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
